Intellect Neurosciences Inc. (fka ILNS)

[cablejohn]

The Company has applied for a patent for its CONJUMAB-A technology
Lonza to Expand Antibody Drug Conjugate (ADC) Manufacturing Capacity to Meet Growing Customer Demand
(CONJUMAB-A is a first-in-class antibody drug conjugate(ADC)
Sep 27, 2012 - Lonza and Intellect Neurosciences Announce Intellect's Intention to Award Production of its Antibody Drug Conjugate, CONJUMAB-A.

28 Sep 2012
Lonza has received a contract from Intellect Neurosciences to develop and manufacture the antibody drug conjugate, Conjumab-A.

Under the contract, Lonza will supply the preclinical study material for the drug optimization and drug selection for Intellect's Conjumab-A, aiming on age-related macular degeneration (AMD) with potential applications for Alzheimer's disease.

The program is also expected to have in vitro and in vivo studies to evaluate both therapeutic and prophylactic potential in AMD testing different chemical variants manufactured by Lonza.

Link for
above;http://specialitychemicals.pharmaceutical-business-review.com/news/lonza-to-develop-antibody-drug-conjugate-280912
We have heard nothing on this, could it have been effected by Pfizers nonpayment? Probably not, but what happened?

Here is Lonza taking about expanding production of ADCs;
Published in: Lonza Website, January 8, 2013
"Lonza today announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland. Oncology therapeutics including ADCs represent one of the fastest growing segments of the pharma and biotech industry and the deployment of ADC targeted therapies has intensified in recent years."

"The expansion of the ADC facility will double the existing large-scale manufacturing capacity in Visp while allowing current operations to continue without interruption. It is the next step in bringing challenging new technologies to one of Lonza’s main sites. The capacity expansion, expected to be complete in the second quarter of 2014, has the potential to bring new job opportunities across all functions in Visp, Switzerland."



Here is Lonza's ADC knowledge page with a huge amount of information;
http://www.lonza.com/custom-manufacturing/chemical-manufacturing/antibody-drug-conjugates-adcs/knowledge-center-for-antibody-drug-conjugates.aspx

We were supposed to have a contract with Lonza as mentioned above for production and development of
CONJUMAB-A and then we heard no more about it...

"CONJUMAB-A is being developed for the treatment of age-related macular degeneration (AMD), the leading cause of blindness in people over the age of 55. CONJUMAB-A also has potential applications for diabetic retinopathy, glaucoma, traumatic brain injury, and Alzheimer's disease."

Put this on the long list of Whats up with that Mr Maza?